Publication | Closed Access
Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study
20
Citations
0
References
2019
Year
Resolve StudyPancreatic CancerGastrointestinal OncologyMetastatic Pancreatic AdenocarcinomaMedicinePharmacologyPharmacotherapyCancer TreatmentOncologyRadiation OncologyPhase 3
No additional data available for this publication yet. Check back later!